Patents by Inventor Dongshan Zhang

Dongshan Zhang has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • METHOD FOR CALCULATING OSCILLATION DAMPING RATIO OF POWER GRID
    Publication number: 20240192256
    Abstract: The present invention disclosed a method for calculating an oscillation damping ratio of a power grid, and relates to the field of power system operation and control. When a power system oscillates, an oscillation period, two oscillation extreme points, and an oscillation direct current component start to be detected. Then an oscillation decay time constant is calculated according to the two oscillation extreme points and the oscillation direct current component. The oscillation damping ratio is calculated through the oscillation decay time constant and the oscillation period. Compared with a conventional fitting method, the conventional fitting method cannot calculate and analyze the oscillation damping ratio in a cast that a complete oscillation waveform is not obtained. The method proposed by the present inventive patent may complete the calculation of the oscillation damping ratio in a case of obtaining 2 pieces of data, so as to accelerate the speed of calculation.
    Type: Application
    Filed: February 23, 2024
    Publication date: June 13, 2024
    Inventors: Yihui ZHANG, Libin WEN, Guangshi LIU, Qian DOU, Dongshan HUANG, Xiaoming WANG, Zhiyuan SUN, Guangling LU, Mingpo LI, Mosi LIU, Hao QIU, Xiaoyin QIU, Zhiyang YAO, Wei ZHANG
  • MOLECULAR MARKER AND KIT FOR EARLY DIAGNOSIS AND PREDICTION OF SEPSIS ACUTE KIDNEY INJURY AND APPLICATION THEREOF
    Publication number: 20190331698
    Abstract: The present invention relates to a molecular marker, a kit and an application for early diagnosis and prediction of sepsis acute kidney injury (AKI). TCONS_00024536 is highly expressed in the blood of sepsis AKI patients. By detecting the expression level of TCONS_00024536 in the blood of patients, whether the patients suffer from sepsis AKI or the probability of suffering from sepsis AKI can be judged. The present invention is of great significance for specific and sensitive early diagnosis and prediction of sepsis AKI.
    Type: Application
    Filed: May 7, 2019
    Publication date: October 31, 2019
    Applicant: THE SECOND XIANGYA HOSPITAL OF CENTRAL SOUTH UNIVERSITY
    Inventors: Dongshan ZHANG, Siyuan QU, Huiling LI, Pan ZHANG
  • 4-heteroaryl substituted benzoic acid compounds as RORgammaT inhibitors and uses thereof
    Patent number: 10196354
    Abstract: The present invention relates to compounds according to Formula I (Formula I), and pharmaceutically acceptable salts or solvates thereof. Such compounds can be used in the treatment of RORgammaT-mediated diseases or conditions.
    Type: Grant
    Filed: July 12, 2017
    Date of Patent: February 5, 2019
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Kenneth J. Barr, Corey E. Bienstock, John K. Maclean, Hongjun Zhang, Richard T. Beresis, Dongshan Zhang, Neville J. Anthony, Blair T. Lapointe, Yuan Tian
  • RORgammaT inhibitors
    Patent number: 9884043
    Abstract: The present invention relates to compounds according to Formula (I) or a pharmaceutically acceptable salt or solvate thereof. Such compounds can be used in the treatment of RORgammaT-mediated diseases or condition.
    Type: Grant
    Filed: March 20, 2017
    Date of Patent: February 6, 2018
    Assignees: Merck Sharp & Dohme Corp., Merck Sharp & Dohme B.V.
    Inventors: Willem Frederik Johan Karstens, Mario Van Der Stelt, Jos Cals, Rita Corte Real Goncalves Azevedo, Kenneth Jay Barr, Hongjun Zhang, Richard Thomas Beresis, Dongshan Zhang, Xiaobang Duan
  • 4-HETEROARYL SUBSTITUTED BENZOIC ACID COMPOUNDS AS RORgammaT INHIBITORS AND USES THEREOF
    Publication number: 20180022701
    Abstract: The present invention relates to compounds according to Formula I (Formula I), and pharmaceutically acceptable salts or solvates thereof. Such compounds can be used in the treatment of RORgammaT-mediated diseases or conditions.
    Type: Application
    Filed: July 12, 2017
    Publication date: January 25, 2018
    Inventors: Kenneth J. Barr, Corey E. Bienstock, John K. Maclean, Hongjun Zhang, Richard T. Beresis, Dongshan Zhang, Neville J. Anthony, Blair T. Lapointe, Yuan Tian
  • RORgammaT INHIBITORS
    Publication number: 20170340610
    Abstract: The present invention relates to compounds according to Formula (I) or a pharmaceutically acceptable salt or solvate thereof. Such compounds can be used in the treatment of RORgammaT-mediated diseases or condition.
    Type: Application
    Filed: March 20, 2017
    Publication date: November 30, 2017
    Inventors: Willem Frederik Johan Karstens, Mario Van Der Stelt, Jos Cals, Rita Corte Real Goncalves, Kenneth Jay Barr, Hongjun Zhang, Richard Thomas Beresis, Dongshan Zhang, Xiaobang Duan
  • 4-heteroaryl substituted benzoic acid compounds as RORgammaT inhibitors and uses thereof
    Patent number: 9745265
    Abstract: The present invention relates to compounds according to Formula I (Formula I), and pharmaceutically acceptable salts or solvates thereof. Such compounds can be used in the treatment of RORgammaT-mediated diseases or conditions.
    Type: Grant
    Filed: August 14, 2013
    Date of Patent: August 29, 2017
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Kenneth J. Barr, Corey E. Bienstock, John K. Maclean, Hongjun Zhang, Richard T. Beresis, Dongshan Zhang, Neville J. Anthony, Blair T. Lapointe, Yuan Tian
  • RORgammaT inhibitors
    Patent number: 9603838
    Abstract: The present invention relates to compounds according to Formula I or a pharmaceutically acceptable salt or solvate thereof. Such compounds can be used in the treatment of RORgammaT-mediated diseases or conditions.
    Type: Grant
    Filed: June 26, 2015
    Date of Patent: March 28, 2017
    Assignees: Merck Sharp & Dohme Corp., Merck Sharp & Dohme B.V.
    Inventors: Willem Frederik Johan Karstens, Mario Van Der Stelt, Jos Cals, Rita Corte Real Goncalves Azevedo, Kenneth Jay Barr, Hongjun Zhang, Richard Thomas Beresis, Dongshan Zhang, Xiaobang Duan
  • 3-cyclohexenyl and cyclohexyl substituted indole and indazole compounds as RORgammaT inhibitors and uses thereof
    Patent number: 9487490
    Abstract: The present invention relates to compounds according to Formula I and pharmaceutically acceptable salts or solvates thereof. Such compounds can be used in the treatment of RORgammaT-mediated diseases or conditions.
    Type: Grant
    Filed: August 14, 2013
    Date of Patent: November 8, 2016
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Kenneth J. Barr, John K. Maclean, Hongjun Zhang, Richard T. Beresis, Dongshan Zhang, Brian M. Andresen, Neville J. Anthony, Blair T. Lapointe, Nunzio Sciammetta
  • RORgammaT INHIBITORS
    Publication number: 20150297566
    Abstract: The present invention relates to compounds according to Formula I or a pharmaceutically acceptable salt or solvate thereof. Such compounds can be used in the treatment of RORgammaT-mediated diseases or conditions.
    Type: Application
    Filed: June 26, 2015
    Publication date: October 22, 2015
    Inventors: Willem Frederik Johan Karstens, Mario Van Der Stelt, Jos Cals, Rita Corte Real Goncalves Azevedo, Kenneth Jay Barr, Hongjun Zhang, Richard Thomas. Beresis, Dongshan Zhang, Xiaobang Duan
  • 4-HETEROARYL SUBSTITUTED BENZOIC ACID COMPOUNDS AS RORgammaT INHIBITORS AND USES THEREOF
    Publication number: 20150218096
    Abstract: The present invention relates to compounds according to Formula I (Formula I), and pharmaceutically acceptable salts or solvates thereof. Such compounds can be used in the treatment of RORgammaT-mediated diseases or conditions.
    Type: Application
    Filed: August 14, 2013
    Publication date: August 6, 2015
    Inventors: Kenneth J. Barr, Corey E. Bienstock, John K. Maclean, Hongjun Zhang, Richard T. Beresis, Dongshan Zhang, Neville J. Anthony, Blair T. Lapointe, Yuan Tian
  • RORgammaT inhibitors
    Patent number: 9095583
    Abstract: The present invention relates to compounds according to Formula (I) or a pharmaceutically acceptable salt or solvate thereof. Such compounds can be used in the treatment of RORgammaT-mediated diseases or condition.
    Type: Grant
    Filed: February 10, 2012
    Date of Patent: August 4, 2015
    Assignees: Merck Sharp & Dohme Corp., Merck Sharp & Dohme B.V.
    Inventors: Willem Frederik Johan Karstens, Mario Van Der Stelt, Jos Cals, Rita Corte Real Goncalves Azevedo, Kenneth Jay Barr, Hongjun Zhang, Richard Thomas Beresis, Dongshan Zhang, Xiaobang Duan
  • 3-CYCLOHEXENYL AND CYCLOHEXYL SUBSTITUTED INDOLE AND INDAZOLE COMPOUNDS AS RORgammaT INHIBITORS AND USES THEREOF
    Publication number: 20150191434
    Abstract: The present invention relates to compounds according to Formula I and pharmaceutically acceptable salts or solvates thereof. Such compounds can be used in the treatment of RORgammaT-mediated diseases or conditions.
    Type: Application
    Filed: August 14, 2013
    Publication date: July 9, 2015
    Inventors: Kenneth J. Barr, John K. Maclean, Hongjun Zhang, Richard T. Beresis, Dongshan Zhang, Brian M. Andresen, Neville J. Anthony, Blair T. Lapointe, Nunzio Sciammetta
  • RORgammaT INHIBITORS
    Publication number: 20140038942
    Abstract: The present invention relates to compounds according to Formula (I) or a pharmaceutically acceptable salt or solvate thereof. Such compounds can be used in the treatment of RORgammaT-mediated diseases or condition.
    Type: Application
    Filed: February 10, 2012
    Publication date: February 6, 2014
    Applicants: Merck Sharp & Dohme B.V., Merck Sharp & Dohme Corp.
    Inventors: Willem Frederik Johan Karstens, Mario Van Der Stelt, Jos Cals, Rita Corte Real Goncalves Azevedo, Kenneth Jay Barr, Hongjun Zhang, Richard Thomas Beresis, Dongshan Zhang, Xiaobang Duan